# First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults

> **NCT07646353** · PHASE1 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 40 (estimated)

## Conditions studied

- Malaria, Falciparum

## Interventions

- **BIOLOGICAL:** GSK4425689A SC
- **BIOLOGICAL:** GSK4425689A IV
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07646353
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-27
- **Primary completion:** 2028-04-10
- **Final completion:** 2028-04-10
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07646353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07646353, "First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07646353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*